Summertime was a busy time of year for FDA medication warnings read the description . That fall is at full pace Now, pharmacists should get familiarized with the drug safety communications sent out this past summer. Listed below are the FDA’since June s medication basic safety alerts, starting with the most recent: 1. Ceftazidime and avibactam The FDA warned pharmacists in past due September that confusion over the drug power of the antibacterial agent Avycaz might lead to medication errors. In response to the confusion, the FDA revised the intravenous drug’s vial and carton labels to specify that all vial contains Avycaz 2.5 g, which is the same as ceftazidime 2 g and avibactam 0.5 g.
Some may have been suitable, said lead writer Dr. Sana Al-Khatib of Duke University School of Medication in Durham, NEW YORK, but it's probably that lots of were done regardless of the research evidence. It's insufficient knowledge. It's ignorance. It's not keeping track of the rules, she said. And we may have some physicians who don't agree with the guidelines or don't believe the guidelines apply to their patients. The scholarly research, showing up in Wednesday's Journal of the American Medical Association, examined nationwide registry data from nearly 112,000 patients in 2006-2009. The researchers discovered that the patients who got implants in accordance to guidelines were less likely to die in the hospital and suffer complications than the sufferers whose surgeries clearly fell beyond your guidelines.